Product Information
DUPIXENT 300 MG/2 ML PEN is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $1009.5592 per ML under NDC 00024591502. Its NADAC has been published 246 times since Jan 19, 2022.
Strength
300 mg/2mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00024591502
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
DUPILUMABApproval Type
Biologic (BLA)
FDA Application
BLA761055On Market Since
6/19/2020
Pharmacological Classes
Price Statistics
The NADAC for DUPIXENT 300 MG/2 ML PEN has been published 246 times since Jan 19, 2022, and over the history we have for it it has risen 25.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1009.5592 per ML |
|---|---|
| All-time high | $1009.5592 (Sep 30, 2026) |
| All-time low | $805.7296 (Jan 19, 2022) |
| 52-week high | $1009.5592 |
| 52-week low | $960.2380 |
| Median price | $917.5096 |
| Average price | $909.7665 |
| Largest weekly change | +6.0% (Jan 10, 2024) |
| Weeks tracked | 246 |
| Tracking since | Jan 19, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dupilumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DUPIXENT 300 MG/2 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for DUPIXENT 300 MG/2 ML PEN, manufactured by Sanofi-Aventis U.S. LLC, is $1009.5592 per ML (NDC 00024591502), effective Sep 30, 2026.
How has the price of DUPIXENT 300 MG/2 ML PEN changed over time?
Over the history we have for it, the NADAC for DUPIXENT 300 MG/2 ML PEN has risen 25.3%. It has been tracked across 246 weekly CMS publications since Jan 19, 2022.
What are the highest and lowest recorded NADAC prices for DUPIXENT 300 MG/2 ML PEN?
Since Jan 19, 2022, the NADAC for DUPIXENT 300 MG/2 ML PEN has ranged from a low of $805.7296 (Jan 19, 2022) to a high of $1009.5592 (Sep 30, 2026), with a median of $917.5096 per ML.
Are there cheaper alternatives to DUPIXENT 300 MG/2 ML PEN?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as DUPIXENT 300 MG/2 ML PEN in a comparable dosage form, but none are currently priced below it.
Who manufactures DUPIXENT 300 MG/2 ML PEN?
DUPIXENT 300 MG/2 ML PEN (NDC 00024591502) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.